Rallybio Corporation (RLYB)
$16.91+1.14%Close
SELLBULL · day 102
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $90M
- Beta
- -0.85
- P/E (TTM)
- 2.13
- Short % float
- 1.71%
- Days to cover
- 4.9
- SI change
- -11.4%
- 1W
- -0.12%
- 1M
- -1.80%
- vs SPY 1W
- +0.02%
- vs SPY 1M
- -4.31%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 21
- GROWTH
- 0
- GARP
- 1
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC41.1%
REV YoY-
ROE68.6%
EPS YoY-
ROA46.5%
GROSS-1108
OP-3672
NET7051
[VALUATION]
P/E TTM2.13
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B1.02
P/FCF-
EV/EBITDA-0.12
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO27.26
ND/EBITDA-
BETA-0.85
Company news
FAQ
- What is LOPJLB’s current signal on RLYB?
- LOPJLB’s latest quantitative signal on Rallybio Corporation (RLYB) is SELL in a BULL regime. Signals are updated daily.
- What market regime is RLYB in?
- Rallybio Corporation (RLYB) is currently classified in the BULL HMM market regime on LOPJLB.
- What does Rallybio Corporation (RLYB) do?
- Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonata…